Psilocybin Administration With 5-HT1a Blockade
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age21-60
SponsorJohns Hopkins University
About this trial
The purpose of this study is to assess the effects of 5-HT1A receptor blockade on the acute subjective effects of psilocybin, as measured through subjective survey measures and acute electroencephalography (EEG). Further, the investigators will assess the effects of psilocybin on post-acute sleep and dreaming through the use of sleep EEG and sleep and dream diaries.
Eligibility criteria
Qualifiers
21 - 60 years old
Must give written or electronic informed consent
Must have at least a high-school level of education or equivalent (e.g. GED) and are fluent in English
Must be healthy and psychologically stable as determined by screening for medical and psychiatric problems via a personal interview, a medical questionnaire, a physical examination, an electrocardiogram (ECG), and routine medical blood and urinalysis laboratory tests
Disqualifiers
Are currently taking a medication with any significant pharmacokinetic or pharmacodynamic interactions with pindolol (e.g. beta-blockers or other anti-hypertensive medications).
Have a history of orthostatic hypotension or low blood-pressure.
Have elevated transaminases (2x the upper limit of normal)
Have a Child-Pugh score that falls within classes B or C.
Trial design
Treatments tested in this trial
- Pindolol
- Placebo
- Psilocybin
Treatment groups
18 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov